Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients in ...

an obscure corner of America’s pharmaceutical market that relies on a legal loophole to produce copies of treatments in short supply. Related: Now at Costco: Ozempic prescriptions for some ...

Shell Canada's decision on whether to pursue Phase 2 of LNG Canada will depend on other opportunities that are available, ...

The injectable drug Ozempic is shown Saturday ... The 503As, however, could exploit a loophole: They can still make semaglutide copies that are not "essential copies" of the drug.

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

A government crackdown on cheaper copies of Ozempic and similar diabetes and weight-loss drugs was intended to shut the door on that booming market. It hasn’t exactly worked out that way.